Tofenacin
Clinical data
Elamol, Tofacine, Tofalin
Other names
tofenacin hydrochloride (USAN US)
Legal status
Identifiers
N-methyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
C17H21NO
255.361 g·mol−1
3D model (JSmol)
O(CCNC)C(c1ccccc1)c2ccccc2C
InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)17(19-13-12-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3
Key:PNYKGCPSFKLFKA-UHFFFAOYSA-N
Tofenacin is an antidepressant drug with a tricyclic-like structure which was developed and marketed in the United Kingdom and Italy in 1971 and 1981, respectively, by Brocades-Stheeman & Pharmacia (now part of Astellas Pharma).[1][2][3] It acts as a serotonin-norepinephrine reuptake inhibitor,[4] and based on its close relation to orphenadrine, may also possess anticholinergic and antihistamine properties. Tofenacin is also the major active metabolite of orphenadrine and likely plays a role in its beneficial effects against depressive symptoms seen in Parkinson's disease patients.[5][6]
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
TeCAsTooltip Tetracyclic antidepressants
Others
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Antagonists
Antagonists
Antagonists
Antagonists
VMATsTooltip Vesicular monoamine transporters
Others
mAChRsTooltip Muscarinic acetylcholine receptors
Precursors
(and prodrugs)
